All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

Pharma Equipment Keeps Up with Trends

November 18, 2015
By Adeline Siew, PhD
Article

Equipment and Processing Report

Equipment and Processing ReportEquipment and Processing Report-11-18-2015
Issue 13

The biotech boom, niche markets, smaller batch sizes, and high potency manufacturing are among the key trends shaping the pharmaceutical industry, and equipment must keep up with features such as fast changeovers and automation.

As medicine spending continues to increase, there is a lot of expectation and pressure on the pharmaceutical industry not just to develop new drugs but also to ensure the quality of their products. But challenges such as patent expiries and the death of blockbuster drugs in an increasingly cost-constrained marketplace mean that players both big and small have to adapt with the changing trends if they want to survive and thrive. 

Biotech boom, niche markets, and a smaller batch size

One of the biggest trends is the move towards biotechnology and personalized medicine, notes Christian Treitel, head of pharma business development and product management at Bosch Packaging Technology. Small-molecule drugs that are chemically synthesized using predictable processes are being replaced by larger, more complex biologics that are produced in living cells and often consist of heterogeneous mixtures. The structure of a chemical API is independent of the manufacturing process but biologics, on the other hand, are defined by the exact manufacturing process, which can be difficult to control from the starting material to the final drug product.

“While this shift opens up new possibilities in medical diagnosis and therapy, we see batch sizes becoming smaller, derived from the need to treat orphan diseases that affect only a small population of patients worldwide,” says Treitel. FDA has played a crucial role in facilitating the development of orphan drugs through its fast-track program. As a result, the industry is moving away from the one-size-fits-all model and investing more into the development of targeted therapies and finding cures for niche diseases. “The researchers embrace it,” says Treitel, “because there are many areas where you can tap on the potential of targeted therapies; however, for the manufacturers, the complexities of production can be a challenge.”

Smaller lots mean more frequent changes, Treitel points out, and changeover takes time. “You have to clean your equipment,” he says, “and then, there is also the additional task of documentation because it is important to make sure that everything is properly documented.”

According to Treitel, customers are now looking for solutions to manage the complexities of modern drug manufacturing, including fast changeovers. “The aim is to make changeover times shorter,” he says. “Basically, you want it to be faster and more convenient for the operators, which is very important.” The new Manesty TPR tablet presses-TPR 200 (for small to medium batches) and TPR 700 (for high production volumes)-from Bosch, for example, have been designed for fast product changeovers, easy cleaning, and simple operation. 

High potency drug manufacturing, isolators, and containment systems

Another key trend is the rapid growth of high potency APIs, which require specialized containment to ensure that both operators and the environment are protected from exposure, observes Treitel. “You want to really make sure that the product is safe and that the operator is safe.”

There has been major breakthrough in isolator and containment systems and pharmaceutical manufacturers recognize the advantages of these technologies (e.g., improved aseptic environments and lower operational costs) compared with conventional clean rooms. “Liquid filling lines are becoming more complex and require integration of the filling machine with an isolator and subsequent machines [such as a freeze dryer or an overseal capping machine],” says Treitel. The challenge is to ensure safe functioning of the interfaces, but at the same time, keep the overall controls system simple and be able to easily operate the individual components. Bosch offers everything from a single source, according Treitel.

For an industry that is highly regulated, quality remains a top priority. “FDA is getting stricter and really checking on pharmaceutical facilities. You often hear of warning letters being issued,” says Treitel. “This means pharmaceutical manufacturers have to work on their quality procedures, and they are looking for support from us-for example, if you are looking to replace your equipment and want certain things to be automated so that manual intervention and human errors can be reduced.”

The relationship between supplier and the pharmaceutical industry is changing, observes Treitel. “As a supplier, it is no longer about supplying single machines but helping the customer to integrate the different pieces of equipment and providing support in implementing projects.” 

Articles in this issue

New Equipment Improves Blister Packaging
fig2b_forweb250.jpg
Best Practices for Optimizing Hopper Performance
Pharma Equipment Keeps Up with Trends
Recent Videos
Behind the Headlines, Episode 17
Related Content

·Mirai Bio and Thermo Fisher are partnering to integrate design, delivery, and CGMP manufacturing for nucleic acid-based therapeutics.  ·The collaboration will leverage Thermo Fisher’s RNA and advanced formulations facility to support scalable development of genetic medicines.  ·Mirai’s machine intelligence platform will be combined with Thermo Fisher’s technical and manufacturing expertise to streamline drug development workflows.

Mirai Bio and Thermo Fisher Partner to Advance Genetic Medicine Manufacturing

Christopher Cole
May 21st 2025
Article

Mirai Bio and Thermo Fisher partner to integrate AI-driven design with CGMP manufacturing, aiming to streamline development of genetic medicines.


Site Logo

Transformations in Drug Development for Cell and Gene Therapies

PPD;Thermo Fisher Scientific
March 28th 2025
Podcast

As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.


Abnormal plasma cell or b-cell in multiple myeloma emitting paraprotein 3d illustration | Image Credit: © LASZLO - stock.adobe.com

CellCentric Completes $120 Million Series C Funding Round for Multiple Myeloma Treatment Inobrodib

Patrick Lavery
May 21st 2025
Article

Inobrodib is being developed as a first-in-class oral cancer drug that the company says will be able to treat not only multiple myeloma, but other specific cancers as well.


Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang

Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang

PPD;Thermo Fisher Scientific
March 28th 2025
Podcast

As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.


Coronavirus Covid-19 background - 3d rendering | Image Credit: © Production Perig - stock.adobe.com

EMA Recommends Update to COVID-19 Vaccines for 2025-26 Campaign

Patrick Lavery
May 19th 2025
Article

The LP.8.1 variant of the SARS-CoV-2 virus differs from the JN.1 family that previous vaccines had been designed to target, and has surpassed JN.1 as the variant circulating most widely worldwide.


IRVINE, CALIFORNIA - 16 APRIL 2020: Student Center and Visitor Center Building on the campus of the University of California Irvine, UCI. | Image Credit: © Steve Cukrov - stock.adobe.com

UC Irvine Lab Studies NLRP3 Inflammasome for Inflammatory Disease Treatment Potential

Patrick Lavery
May 19th 2025
Article

Researchers say they have discovered the first drug mechanism that binds to the pyrin domain to block NLRP3 and prevent a series of reactions resulting in inflammation.

Related Content

·Mirai Bio and Thermo Fisher are partnering to integrate design, delivery, and CGMP manufacturing for nucleic acid-based therapeutics.  ·The collaboration will leverage Thermo Fisher’s RNA and advanced formulations facility to support scalable development of genetic medicines.  ·Mirai’s machine intelligence platform will be combined with Thermo Fisher’s technical and manufacturing expertise to streamline drug development workflows.

Mirai Bio and Thermo Fisher Partner to Advance Genetic Medicine Manufacturing

Christopher Cole
May 21st 2025
Article

Mirai Bio and Thermo Fisher partner to integrate AI-driven design with CGMP manufacturing, aiming to streamline development of genetic medicines.


Site Logo

Transformations in Drug Development for Cell and Gene Therapies

PPD;Thermo Fisher Scientific
March 28th 2025
Podcast

As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.


Abnormal plasma cell or b-cell in multiple myeloma emitting paraprotein 3d illustration | Image Credit: © LASZLO - stock.adobe.com

CellCentric Completes $120 Million Series C Funding Round for Multiple Myeloma Treatment Inobrodib

Patrick Lavery
May 21st 2025
Article

Inobrodib is being developed as a first-in-class oral cancer drug that the company says will be able to treat not only multiple myeloma, but other specific cancers as well.


Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang

Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang

PPD;Thermo Fisher Scientific
March 28th 2025
Podcast

As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.


Coronavirus Covid-19 background - 3d rendering | Image Credit: © Production Perig - stock.adobe.com

EMA Recommends Update to COVID-19 Vaccines for 2025-26 Campaign

Patrick Lavery
May 19th 2025
Article

The LP.8.1 variant of the SARS-CoV-2 virus differs from the JN.1 family that previous vaccines had been designed to target, and has surpassed JN.1 as the variant circulating most widely worldwide.


IRVINE, CALIFORNIA - 16 APRIL 2020: Student Center and Visitor Center Building on the campus of the University of California Irvine, UCI. | Image Credit: © Steve Cukrov - stock.adobe.com

UC Irvine Lab Studies NLRP3 Inflammasome for Inflammatory Disease Treatment Potential

Patrick Lavery
May 19th 2025
Article

Researchers say they have discovered the first drug mechanism that binds to the pyrin domain to block NLRP3 and prevent a series of reactions resulting in inflammation.

About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.